These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1710385)

  • 21. Drug treatments for spasticity.
    Yelnik AP; Simon O; Bensmail D; Chaleat-Valayer E; Decq P; Dehail P; Quentin V; Marque P; Parratte B; Pellas F; Rousseaux M; Trocello JM; Uzzan M; Dumarcet N;
    Ann Phys Rehabil Med; 2009 Dec; 52(10):746-56. PubMed ID: 19892619
    [No Abstract]   [Full Text] [Related]  

  • 22. Maudsley rat strains, selected for differences in emotional responses, differ in behavioral response to clonidine and in [125I]clonidine binding in the locus coeruleus.
    Sara SJ; Devauges V; Biegon A
    Behav Brain Res; 1993 Oct; 57(1):101-4. PubMed ID: 8292249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Spastic syndrome and main directions of its treatment].
    Damulin IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(12):4-9. PubMed ID: 14763249
    [No Abstract]   [Full Text] [Related]  

  • 24. Managing spasticity with drugs.
    Simon O; Yelnik AP
    Eur J Phys Rehabil Med; 2010 Sep; 46(3):401-10. PubMed ID: 20927006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The neuroanatomy and pharmacology of the nucleus locus coeruleus.
    Grant SJ; Redmond DE
    Prog Clin Biol Res; 1981; 71():5-27. PubMed ID: 6276901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Changes in spino-bulbo-spinal reflexes during activation and inactivation of the locus coeruleus in the cat].
    Vankov A; Gokin AP; Piliavskiĭ AI; Iakhnitsa IA
    Neirofiziologiia; 1984; 16(2):265-8. PubMed ID: 6738752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alpha adrenergic and serotonergic agents in the treatment of spastic hypertonia.
    Nance PW
    Phys Med Rehabil Clin N Am; 2001 Nov; 12(4):889-905. PubMed ID: 11723869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of drugs potentiating or inhibiting the activity of locus coeruleus neurons on various types of spinal inhibition in the cat].
    Iakhnitsa IA; Bulgakova NV; Piliavskiĭ AI
    Neirofiziologiia; 1981; 13(3):247-58. PubMed ID: 7279046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spasticity: revisiting the role and the individual value of several pharmacological treatments.
    Lapeyre E; Kuks JB; Meijler WJ
    NeuroRehabilitation; 2010; 27(2):193-200. PubMed ID: 20871149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The spinal pathophysiology of spasticity--from a basic science point of view.
    Nielsen JB; Crone C; Hultborn H
    Acta Physiol (Oxf); 2007 Feb; 189(2):171-80. PubMed ID: 17250567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder.
    Arnsten AF; Steere JC; Hunt RD
    Arch Gen Psychiatry; 1996 May; 53(5):448-55. PubMed ID: 8624188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of cyclobenzaprine on the locus ceruleus.
    Gintautas J; Barnes CD
    Proc West Pharmacol Soc; 1979; 22():37-41. PubMed ID: 515073
    [No Abstract]   [Full Text] [Related]  

  • 33. [Medical treatment of spasticity].
    Rode G; Maupas E; Luaute J; Courtois-Jacquin S; Boisson D
    Neurochirurgie; 2003 May; 49(2-3 Pt 2):247-55. PubMed ID: 12746699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impaired efficacy of spinal presynaptic mechanisms in spastic stroke patients.
    Lamy JC; Wargon I; Mazevet D; Ghanim Z; Pradat-Diehl P; Katz R
    Brain; 2009 Mar; 132(Pt 3):734-48. PubMed ID: 19036767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Total neurochemical lesion of noradrenergic neurons of the locus ceruleus does not alter either naloxone-precipitated or spontaneous opiate withdrawal nor does it influence ability of clonidine to reverse opiate withdrawal.
    Caillé S; Espejo EF; Reneric JP; Cador M; Koob GF; Stinus L
    J Pharmacol Exp Ther; 1999 Aug; 290(2):881-92. PubMed ID: 10411605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spasticity: current and future management. Royal College of Physicians, November 13, 1997.
    Hosp Med; 1998 Jan; 59(1):61-9. PubMed ID: 9798568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Electrophysiological analysis of the mode of action of muscle relaxants in spasticity.
    Delwaide PJ
    Ann Neurol; 1985 Jan; 17(1):90-5. PubMed ID: 3985591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
    Smolenski C; Muff S; Smolenski-Kautz S
    Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clonidine treatment of the opiate withdrawal syndrome. A review of clinical trials of a theory.
    Agren H
    Acta Psychiatr Scand Suppl; 1986; 327():91-113. PubMed ID: 3529831
    [No Abstract]   [Full Text] [Related]  

  • 40. The primate locus coeruleus and effects of clonidine on opiate withdrawal.
    Redmond DE; Huang YH
    J Clin Psychiatry; 1982 Jun; 43(6 Pt 2):25-9. PubMed ID: 6282817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.